Original news and analysis on international IP policy
BRUSSELS - In 2014, patent filings at the European Patent Office (EPO) reached an all-time high, as announced by EPO President Benoît Battistelli last week at the traditional Annual Results Press Conference. Among key patenting trends were figures revealing strong growth in filings from the United States and China.
An initiative spearheaded by the Global Fund for AIDS, Tuberculosis and Malaria to ensure equitable access to medicines in particular in middle-income countries now has a dedicated webpage publishing the terms of reference of the initiative. Also available is the list of high-level participants who attended the first meeting of the initiative held last week.
Although there are ongoing negotiations to revise the Lisbon Agreement for the international recognition of GIs, there is currently no uniform reciprocal legal recognition for non-wine and spirit GIs in international jurisdictions. Jamaica’s Cannabis (hereafter marijuana), is identified by its government as one of the country’s products which is domestically GI registrable, writes Marsha Cadogan.
Experts gathered in Geneva recently to discuss current issues and future developments in the protection of industrial designs and its importance, and give practical advice on suitable ways to protect and enforce the design rights.
According to a public health advocacy group, there are now as many as 10 oppositions filed at the European Patent Office against the Gilead company's patent on sofosbuvir, a treatment for hepatitis C. The group has compiled a table showing the filings with links to the documents.
Ellen 't Hoen writes: On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request for an extension of the transitional period under article 66.1 TRIPS with respect to pharmaceutical products until the country is no longer classified as LDC.[1] The original extension, set to expire on 1st January 2016, specifically removes the obligation for LDCs to comply with Section 5 (Patents) and Section 7 (Protection of Undisclosed Information) of Part II of TRIPS, including any obligation to enforce rights under these provisions.
It is a little known fact that since the adoption of the 2001 Doha Declaration on TRIPS and Public Health, LDCs have frequently used the extension in day-to-day procurement of low cost generic medicines, in particular to access medicines needed for the treatment of HIV.
CAPE TOWN - South Africa’s new policy on patents could go to the Cabinet for approval soon, says Doctors without Borders (Médecins Sans Frontières, MSF), one of the organisations spearheading the Fix the Patent Laws campaign in the country.
According to an internal report of the United Nations Development Programme (UNDP) Global Fund Partnership team, the Ebola epidemic has virtually halted national HIV efforts in Sierra Leone. In particular, patients stopped their treatments and the supply chain was disrupted.
Recommendations for key reforms to laws against “groundless threats” of infringement lawsuits in patent, trademark and design rights cases won general UK government backing today. IP lawyers said the government's stance will go far toward resolving longstanding concerns.
The issue of plain packaging for tobacco products as a health measure has been smouldering at the World Trade Organization since Australia decided to implement legislation requiring plain packaging in 2012. Now, as more countries seek to enact similar legal provisions, some tobacco producing countries continue to try to stub them out, including at the WTO intellectual property committee.
This week at the World Trade Organization intellectual property committee meeting, least-developed countries submitted a request to extend a waiver allowing them not to enforce intellectual property rights on pharmaceutical products. The countries have extended the waiver before, but this time they are seeking to make it indefinite, until they are no longer considered LDCs.
This week a confidential high-level expert meeting was convened in Geneva to start work on a potential change in the country classification used by global health actors to remedy the growing problem of access to medicines in middle-income countries.